
Opinion|Videos|February 27, 2025
Beyond HER2: Expanding the Biomarker Testing Landscape in Metastatic Breast Cancer
Panelists discuss how HER2 testing optimization requires multisite sampling and quantitative assessment methods to account for intratumoral heterogeneity. Beyond HER2, biomarkers such as PI3K mutations, hormone receptor status, and tumor mutational burden can guide therapy selection for metastatic breast cancer (mBC), enabling more personalized treatment approaches.
Advertisement
Episodes in this series

Video content above has been prompted by the following:
- How can we optimize HER2 testing and antibody-drug conjugate treatment selection considering tumor heterogeneity across different cancer sites?
- Are there additional biomarkers beyond HER2 that can help guide mBC therapy selection?
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Yes, COVID-19 Is Still a Big Deal. Pharmacy Is the Tip of the Spear (and Needle)
2
Beat the Heat: 10 Common Medication Culprits Causing Heat Intolerance
3
FDA Fast Tracks First-in-Class TNFR2 Antibody as Chemotherapy-Free Strategy for Platinum-Resistant Ovarian Cancer
4
The Inflation Reduction Act and Oncology Drug Pricing: What Pharmacists Need to Know
5



































































































